On November 9, 2020 Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, reported the trial design of its ongoing Phase 1/2 clinical trial and preclinical data demonstrating proofof-concept of its lead clinical drug candidate, BDC-1001 (Press release, Bolt Biotherapeutics, NOV 9, 2020, View Source [SID1234570446]). The clinical observations and preclinical data are now available in three posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, being held virtually November 9-14.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud to present our recent scientific advances at the SITC (Free SITC Whitepaper) Annual Meeting highlighting that systemically-delivered trastuzumab ISACs induce a robust, target-dependent activation of the immune system in preclinical models as well as further mechanistic insight for the observed robust anti-tumor activity, said David Dornan, senior vice president of research and manufacturing at Bolt. "We hope to confirm the promising results from our preclinical work in our clinical trial that is currently ongoing."
The in-progress clinical trial poster titled, "Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors," highlighted the framework of Bolt’s Phase 1/2 clinical trial, an actively enrolling global study in patients with refractory HER2-expressing solid tumors. The primary objectives of the study are to evaluate safety and tolerability and determine the recommended Phase 2 dose for both monotherapy and combination with a checkpoint inhibitor. BDC-1001 is a novel treatment which combines the targeting and antitumor effect of trastuzumab with localized stimulation of the immune system via dual TLR7 and TLR8 agonism.
The preclinical results were shown in two posters. The first titled, "Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR-and TLRsignaling and enables safe systemic administration," demonstrated that Bolt’s immune stimulating antibody conjugates (ISACs) are safe and well-tolerated in mice and non-human primates. The ISACs enable potent tolllike receptor (TLR) agonists to be safely administered systemically in preclinical models. ISACs provided distinct and unexpected biological advantage over unconjugated TLR agonists leading to more robust and effective antitumor efficacy.
The final poster titled, "Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models," demonstrated that within 24 hours of administration, HER2-directed ISACs induced robust, target-dependent activation of the immune system. There was robust activation of immune cells following anti-HER2 ISAC treatment. In contrast to other immune therapies, such as anti-PD1/PD-L1 and anti-CD40, systemically administered ISACs locally engage both the innate and adaptive immune system to eradicate tumors.
"These preclinical data further validate our tumor-targeting BDC-1001 Boltbody ISAC as a promising candidate to treat HER2-expressing solid tumors in our ongoing Phase 1/2 trial. Recruitment is going well thanks to our dedicated investigators and patients," said Edith Perez, M.D., Chief Medical Officer at Bolt. "We look forward to reporting the initial data readout of our clinical trial soon."
About Bolt Biotherapeutics’ Immune Stimulating Antibody Conjugate (ISAC) Platform Technology The BoltbodyTM ISAC platform technology harnesses the ability of innate immune agonists to convert cold tumors into immunologically hot tumors, thereby illuminating tumors to the immune system and allowing them to be invaded by tumor killing cells. Boltbody ISACs have demonstrated the ability to eliminate tumors following systemic administration as monotherapy in preclinical models and have also led to the development of immunological memory, which is predicted to translate into more durable clinical responses for patients.
About the Ongoing BDC-1001 Phase 1/2 Study in Patients with HER2-Expressing Solid Tumors The Phase 1/2, multi-center, open-label study is evaluating the safety, pharmacokinetics, pharmacodynamics and proof of mechanism of BDC-1001 in patients with HER2-expressing solid tumors. The first portion of the study includes a monotherapy dose-escalation phase in which cohorts of patients will receive ascending intravenous doses of BDC-1001 to determine the maximum tolerated dose and/or the recommended dose to advance into expansion cohorts and Phase 2 based on safety and tolerability. The second portion of the study is a dose expansion phase in which patients will receive BDC-1001 monotherapy to further evaluate the safety, tolerability and clinical antitumor activity of the recommended Phase 2 dose. Please refer to www.clinicaltrials.gov NCT04278144 for additional clinical trial information.